一项回顾性、多机构「目标试验模拟」:比较复苏后肾上腺素与去甲肾上腺素
该研究采用目标试验模拟方法,纳入2018—2022年ESO数据协作组中18—80岁非创伤性院外心脏骤停且复苏后记录有去甲肾上腺素或肾上腺素输注的成人患者,比较两种院前升压药与再停搏和死亡的关系。共1893例患者(309个急救机构)纳入分析,1010例(53.4%)初始使用肾上腺素输注,883例(46.7%)使用去甲肾上腺素输注。校正分析未发现升压药种类与再停搏(aOR 0.93 [0.72, 1.21])或死亡(aOR 1.00 [0.59, 1.69])存在关联。结论认为复苏后肾上腺素输注与去甲肾上腺素输注相比,未增加再停搏的比值。
要点
- 共1893例院外心脏骤停复苏后患者,1010例(53.4%)初始用肾上腺素输注,883例(46.7%)用去甲肾上腺素输注。
- 校正后升压药种类与再停搏无显著关联:aOR 0.93(95%CI 0.72–1.21)。
- 校正后升压药种类与死亡无显著关联:aOR 1.00(95%CI 0.59–1.69)。
- 研究采用目标试验模拟方法,校正了Utstein因素、派遣至ROSC间隔、ROSC至升压药间隔及随访间隔。
适用人群与场景
- 2018—2022年ESO数据协作组中18—80岁非创伤性院外心脏骤停患者,且记录有复苏后去甲肾上腺素或肾上腺素输注。
研究设计与关键结果
- 研究类型:回顾性、多机构目标试验模拟;数据来源:2018—2022年ESO数据协作组;纳入1893例患者,来自309个急救机构。
- 分组:1010例(53.4%)初始使用肾上腺素输注,883例(46.7%)初始使用去甲肾上腺素输注。
- 主要终点:校正后升压药种类与再停搏无显著关联(aOR 0.93 [95%CI 0.72, 1.21]);与死亡无显著关联(aOR 1.00 [95%CI 0.59, 1.69])。
- 校正变量:第一套包括标准Utstein因素、派遣至ROSC间隔、ROSC至升压药间隔及随访间隔;第二套另加院前收缩压和SpO2值。
- 另采用Kaplan-Meier时间-事件分析和多变量Cox回归模型比较两组。
证据类型、等级与局限
- 证据类型:回顾性、多机构目标试验模拟。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在此多机构目标试验模拟中,复苏后肾上腺素输注与去甲肾上腺素输注相比,未增加再停搏的比值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Epinephrine and norepinephrine are the two most commonly used prehospital vasopressors in the United States. Prior studies have suggested that use of a post-ROSC epinephrine infusion may be associated with increased rearrest and mortality in comparison to use of norepinephrine. We used target trial emulation methodology to compare the rates of rearrest and mortality between the groups of OHCA patients receiving these vasopressors in the prehospital setting.
METHODS: Adult (18-80 years of age) non-traumatic OHCA patients in the 2018-2022 ESO Data Collaborative datasets with a documented post-ROSC norepinephrine or epinephrine infusion were included in this study. Logistic regression modeling was used to evaluate the association between vasopressor agent and outcome using two sets of covariables. The first set of covariables included standard Utstein factors, the dispatch to ROSC interval, the ROSC to vasopressor interval, and the follow-up interval. The second set added prehospital systolic blood pressure and SpO2 values. Kaplan-Meier time-to-event analysis was also conducted and the vasopressor groups were compared using a multivariable Cox regression model.
RESULTS: Overall, 1,893 patients treated by 309 EMS agencies were eligible for analysis. 1,010 (53.4%) received an epinephrine infusion and 883 (46.7%) received a norepinephrine infusion as their initial vasopressor. Adjusted analyses did not discover an association between vasopressor agent and rearrest (aOR: 0.93 [0.72, 1.21]) or mortality (aOR: 1.00 [0.59, 1.69]).
CONCLUSIONS: In this multi-agency target trial emulation, the use of a post-resuscitation epinephrine infusion was not associated with increased odds of rearrest in comparison to the use of a norepinephrine infusion.
参考来源
- Smida T, Crowe RP, Martin PS, et al. A retrospective, multi-agency 'target trial emulation' for the comparison of post-resuscitation epinephrine to norepinephrine. Resuscitation. 2024. PMID: 38582437. doi:10.1016/j.resuscitation.2024.110201
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。